Alnylam stock price target raised to $500 from $435 at RBC Capital

RBC Capital raised its price target on Alnylam Pharmaceuticals (ALNY) to $500, citing robust Amvuttra sales, with August figures at $167 million and RBC's Q3 estimate of $700 million significantly exceeding consensus, leading to an increased peak sales projection of $9.3 billion. This positive outlook is further supported by BMO Capital's target increase to $470 following strong Phase II results for the hypertension candidate Zilebesiran and Alnylam's recent $575 million convertible note offering, collectively signaling strong operational momentum and pipeline potential for the company.

Analysis

Alnylam Pharmaceuticals (ALNY) is demonstrating significant commercial momentum and pipeline maturation, prompting bullish analyst revisions. RBC Capital has increased its price target to $500, underpinned by exceptionally strong sales for its drug Amvuttra, which generated $167 million in August, reflecting a 17% month-over-month increase and a 238% jump since its cardiomyopathy launch in February. This performance has led RBC to forecast third-quarter sales of $700 million, substantially above the consensus estimate of $560 million, and to raise its peak sales projection for the drug to $9.3 billion. This outlook is supported by a physician survey indicating minimal payer resistance and a clinical preference for Amvuttra's mechanism. Further bolstering the positive thesis, BMO Capital raised its target to $470 following promising Phase II results for Zilebesiran, a hypertension candidate, which diversifies the company's growth narrative. Alnylam's strategic financial management is also evident in its upsized $575 million convertible senior notes offering, signaling strong investor confidence and securing capital for future development.

Key Decisions for Investors

• Investors should recognize the potential for a significant earnings beat in Q3, as leading analyst sales forecasts for Amvuttra are tracking approximately 25% above consensus, which could serve as a powerful near-term stock catalyst.
• Monitor Alnylam's upcoming earnings report for an official upward revision to its full-year TTR franchise guidance, which analysts anticipate could increase by around $300 million, to validate the current bullish thesis.
• Evaluate the company's long-term value beyond the immediate Amvuttra success, as positive Phase II data for hypertension drug Zilebesiran de-risks a major secondary growth driver, and the recent capital raise secures the financial runway for pipeline execution.